Skip to main content
$30M deal to acquire CellRight completed by Tissue Regenix

The approximately $30 million acquisition of CellRight Technologies, along with its spinal surgery and orthopedic portfolio, was completed by England-based Tissue Regenix. The transaction helps position Tissue Regenix for the release early next year of its OrthoPure HT decellularized human tendon in the US to address repair of cruciate ligaments, the company said.

Full Story: